Genelux (GNLX) Total Liabilities (2022 - 2026)
Genelux (GNLX) posted Total Liabilities of $9.5 million for Q1 2026, up 26.3% on a QoQ basis from $7.5 million in Q4 2025, and up 131.67% year-over-year from $4.1 million in Q1 2025.
Analysis
Genelux (GNLX) Total Liabilities (2022 - 2026) Analysis & Trends
Genelux has reported Total Liabilities for 5 years, with the latest figure at $9.5 million in Q1 2026.
- On a quarterly basis, Total Liabilities rose 131.67% year-over-year to $9.5 million in Q1 2026; TTM through Mar 2026 was $9.5 million, a 131.67% increase from a year earlier, with the FY2025 full-year figure at $7.5 million, down 11.36% from the prior year.
- Total Liabilities was $9.5 million for Q1 2026 at Genelux, up from $7.5 million in the prior quarter.
- The five-year high for Total Liabilities was $41.3 million in Q4 2022, with the low at -$200.0 million in Q1 2023.
- Average Total Liabilities over 5 years is -$18.2 million, with a median of $8.3 million recorded in 2025.
- The sharpest annual moves came in 2025 and 2026: Total Liabilities plunged 411.16% in 2025, then surged 131.67% in 2026.
- Over 5 years, Total Liabilities stood at $41.3 million in 2022, then slumped by 79.62% to $8.4 million in 2023, then climbed by 0.26% to $8.4 million in 2024, then slipped by 11.36% to $7.5 million in 2025, then grew by 26.3% to $9.5 million in 2026.
- The last three Total Liabilities figures came in at $9.5 million (Q1 2026), $7.5 million (Q4 2025), and $6.4 million (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 83.95 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 37.53 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 7.18 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 10.02 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 1.62 Bn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 4.20 Bn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 4.20 Bn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 13.24 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | 384.62 Mn |
| 10 | Genelux | 108.17 Mn | 108.17 Mn | - | 9.45 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 9.45 Mn |
| Dec 31, 2025 | 7.48 Mn |
| Sep 30, 2025 | 6.40 Mn |
| Jun 30, 2025 | 8.35 Mn |
| Mar 31, 2025 | -29.85 Mn |
| Dec 31, 2024 | 8.44 Mn |
| Sep 30, 2024 | 7.18 Mn |
| Jun 30, 2024 | 7.51 Mn |
| Mar 31, 2024 | 9.59 Mn |
| Dec 31, 2023 | 8.42 Mn |
| Sep 30, 2023 | 10.04 Mn |
| Jun 30, 2023 | -200.00 Mn |
| Mar 31, 2023 | -200.00 Mn |
| Dec 31, 2022 | 41.31 Mn |
| Sep 30, 2022 | 32.33 Mn |